Greenwich LifeSciences announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to June 30, 2025 which is approximately 57 months from date of the Company’s IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company’s common stock unless otherwise modified by the Board of Directors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GLSI:
- Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe
- Greenwich LifeSciences’ Flamingo-01 Phase 3 trial expanding in Europe
- Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries
- Greenwich LifeSciences’ Phase 3 trial protocol accepted by European regulators
- Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators
